Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01772472 · OUTCOME

Median Duration of Trastuzumab Emtansine Exposure

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE) · Source last updated 2025-07-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
Full Range
Time frame
Up to 12 months

What was measured

Treatment duration was defined as the time between the first and the last infusion of trastuzumab emtansine.

Analysis population: SE population included all randomized participants who received any amount of study treatment.

Groups in this outcome

Trastuzumab Emtansine

Participants received trastuzumab emtansine, 3.6 mg/kg, IV, Q3W for 14 cycles (1 cycle = 21 days) or until disease recurrence or unacceptable toxicity which ever occurs first.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Trastuzumab Emtansine740

Reported measurements

Source class 1
Values in months · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Trastuzumab Emtansine10Not reported112Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1
        upper Limit
        12
        value
        10
denoms
  1. counts
    1. group Id
      OG000
      value
      740
    units
    Participants
description
Treatment duration was defined as the time between the first and the last infusion of trastuzumab emtansine.
dispersion Type
Full Range
groups
  1. description
    Participants received trastuzumab emtansine, 3.6 mg/kg, IV, Q3W for 14 cycles (1 cycle = 21 days) or until disease recurrence or unacceptable toxicity which ever occurs first.
    id
    OG000
    title
    Trastuzumab Emtansine
param Type
MEDIAN
population Description
SE population included all randomized participants who received any amount of study treatment.
reporting Status
POSTED
time Frame
Up to 12 months
title
Median Duration of Trastuzumab Emtansine Exposure
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice